Samsung Biologics has entered into a service agreement with Panolos Bioscience to develop PB101, an Fc-fusion protein intended to treat solid tumors. Samsung Biologics will provide a full scope of development services from cell line development, process development, to non-clinical and clinical material manufacturing.
All rights are reserved by the media that published this article.
Samsung Biologics has entered into a service agreement with Panolos Bioscience to develop PB101, an Fc-fusion protein intended to treat solid tumors. Samsung Biologics will provide a full scope of development services from cell line development, process development, to non-clinical and clinical material manufacturing.
All rights are reserved by the media that published this article.